ABBV vs VRT: Which Is the Better Buy?

Side-by-side comparison of AbbVie Inc. and Vertiv Holdings Co — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-04-29.
AbbVie Inc. · Healthcare
$197.69
+6.3% upside to fair value
Grade C High Quality
VS
Vertiv Holdings Co · Industrials
$305.14
-45.0% upside to fair value
Grade D High Quality
QuantHub Verdict
ABBV has more upside to fair value (+6.3%). VRT trades at a lower forward P/E (75.0x). These are model outputs — not personalized investment advice. See all research →
Valuation & Fundamentals
Metric ABBV VRT
Current Price $197.69 $305.14
Fair Value Estimate $210.22 $167.83
Upside to Fair Value +6.3% -45.0%
Market Cap $349.7B $116.8B
Forward P/E 83.3x 75.0x
EV / EBITDA 23.4x 50.1x
Price / Sales 5.7x 10.8x
Price / FCF 18.7x 50.5x
Revenue Growth YoY +10.0% +30.1%
Gross Margin 70.2% 36.2%
Operating Margin 26.7% 18.5%
Return on Equity -361.6% 42.1%
Dividend Yield 0% 0%
FCF Yield 5.35% 1.98%
Analyst Consensus Strong Buy Strong Buy
Investment Thesis
ABBV — AbbVie Inc.
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology, neuroscience, oncology, and aesthetics. The company benefits from a durable competitive moat driven by blockbuster drugs such as Skyrizi and Rinvoq, which are experiencing rapid growth and offsetting declines from Humira due to biosimilar competition. Despite a high trailing and forwa…
VRT — Vertiv Holdings Co
Vertiv Holdings Co operates in the electrical equipment and parts industry within the industrials sector, focusing on critical digital infrastructure technology products and services. The company has demonstrated strong business quality with a 42.1% return on equity, 30.1% revenue growth, and 137.1% earnings growth in the most recent quarter, supported by solid margins including a 36.2% gross mar…
Accumulation Zones
Metric ABBV VRT
Zone Low $157.66 $125.87
Zone High $178.69 $142.66
In Buy Zone? No No
← ABBV Research    VRT Research →    All Research